122 related articles for article (PubMed ID: 23425295)
1. Cost effectiveness of liposomal doxorubicin vs. paclitaxel for the treatment of advanced AIDS-Kaposi's sarcoma.
Raimundo K; Biskupiak J; Goodman M; Silverstein S; Asche C
J Med Econ; 2013; 16(5):606-13. PubMed ID: 23425295
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi's sarcoma in Brazil.
Vanni T; Fonseca BA; Polanczyk CA
HIV Clin Trials; 2006; 7(4):194-202. PubMed ID: 17065031
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma.
Bennett CL; Golub RM; Stinson TJ; Aboulafia DM; von Roenn J; Bogner J; Goebel FD; Stewart S
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):460-5. PubMed ID: 9715842
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel for treating KS.
Proj Inf Perspect; 1997 Nov; (23):15. PubMed ID: 11365372
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma.
Hjortsberg C; Persson U; Lidbrink E; Bennett C
Acta Oncol; 1999; 38(8):1063-7. PubMed ID: 10665764
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.
Cooley T; Henry D; Tonda M; Sun S; O'Connell M; Rackoff W
Oncologist; 2007 Jan; 12(1):114-23. PubMed ID: 17227906
[TBL] [Abstract][Full Text] [Related]
7. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.
Tulpule A; Groopman J; Saville MW; Harrington W; Friedman-Kien A; Espina BM; Garces C; Mantelle L; Mettinger K; Scadden DT; Gill PS
Cancer; 2002 Jul; 95(1):147-54. PubMed ID: 12115328
[TBL] [Abstract][Full Text] [Related]
8. Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. Caelyx/KS Spanish Study Group.
Núñez M; Machuca A; Soriano V; Podzamczer D; González-Lahoz J
AIDS; 2000 May; 14(8):913-9. PubMed ID: 10853972
[TBL] [Abstract][Full Text] [Related]
9. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.
Northfelt DW; Dezube BJ; Thommes JA; Miller BJ; Fischl MA; Friedman-Kien A; Kaplan LD; Du Mond C; Mamelok RD; Henry DH
J Clin Oncol; 1998 Jul; 16(7):2445-51. PubMed ID: 9667262
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.
Duggan ST; Keating GM
Drugs; 2011 Dec; 71(18):2531-58. PubMed ID: 22141391
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
Amantea MA; Forrest A; Northfelt DW; Mamelok R
Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455
[TBL] [Abstract][Full Text] [Related]
12. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
Coukell AJ; Spencer CM
Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
[TBL] [Abstract][Full Text] [Related]
13. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain.
Ojeda B; de Sande LM; Casado A; Merino P; Casado MA
Br J Cancer; 2003 Sep; 89(6):1002-7. PubMed ID: 12966416
[TBL] [Abstract][Full Text] [Related]
14. Management of AIDS-related Kaposi's sarcoma: advances in target discovery and treatment.
Dezube BJ
Expert Rev Anticancer Ther; 2002 Apr; 2(2):193-200. PubMed ID: 12113241
[TBL] [Abstract][Full Text] [Related]
15. Liposomal chemotherapies.
Smart T
GMHC Treat Issues; 1995; 9(7/8):13. PubMed ID: 11362653
[TBL] [Abstract][Full Text] [Related]
16. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy.
Núñez M; Saballs P; Valencia ME; Santos J; Ferrer E; Santos I; Berrocal A; Galindo MJ; Podzamczer D; Gonzlez-Lahoz J;
HIV Clin Trials; 2001; 2(5):429-37. PubMed ID: 11673818
[TBL] [Abstract][Full Text] [Related]
17. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma.
Sharpe M; Easthope SE; Keating GM; Lamb HM
Drugs; 2002; 62(14):2089-126. PubMed ID: 12269857
[TBL] [Abstract][Full Text] [Related]
18. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
[TBL] [Abstract][Full Text] [Related]
19. AIDS-related Kaposi's sarcoma: a phase II study of liposomal doxorubicin. The TLC D-99 Study Group.
Cheung TW; Remick SC; Azarnia N; Proper JA; Barrueco JR; Dezube BJ
Clin Cancer Res; 1999 Nov; 5(11):3432-7. PubMed ID: 10589755
[TBL] [Abstract][Full Text] [Related]
20. [Refractory AIDS-associated Kaposi's sarcoma treated successfully with paclitaxel: a case report].
Kato H; Yanagisawa N; Sasaki S; Hosoda T; Suganuma A; Imamura A; Ajisawa A
Kansenshogaku Zasshi; 2012 May; 86(3):287-90. PubMed ID: 22746051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
